Literature DB >> 19180266

Cdc7 as a potential new target for cancer therapy.

Sayuri Ito1, Chika Taniyami, Naoko Arai, Hisao Masai.   

Abstract

Cdc7 kinase plays crucial roles in firing of replication origins and in proper maintenance of replication forks, which are the sites of DNA replication. The inactivation of Cdc7 causes destabilization of replication forks leading to acute genomic instability and induces massive cell death preferentially in cancer cells. Thus, Cdc7 kinase may be a promising novel target for cancer therapy. Indeed, the first classes of Cdc7 inhibitors have been reported and have been shown to be effective in delaying tumor growth in animal models. Copyright 2008 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19180266     DOI: 10.1358/dnp.2008.21.9.1290818

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  11 in total

1.  MiR-200a with CDC7 as a direct target declines cell viability and promotes cell apoptosis in Wilm's tumor via Wnt/β-catenin signaling pathway.

Authors:  Xiu-Ling Liang; Yu-Long Wang; Pei-Rong Wang
Journal:  Mol Cell Biochem       Date:  2021-02-18       Impact factor: 3.396

2.  Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models.

Authors:  Alessandro Natoni; Mark R E Coyne; Alan Jacobsen; Michael D Rainey; Gemma O'Brien; Sandra Healy; Alessia Montagnoli; Jürgen Moll; Michael O'Dwyer; Corrado Santocanale
Journal:  Cancers (Basel)       Date:  2013-07-24       Impact factor: 6.639

3.  A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response.

Authors:  Jennifer FitzGerald; Laura S Murillo; Gemma O'Brien; Enda O'Connell; Aisling O'Connor; Kevin Wu; Guan-Nan Wang; Michael D Rainey; Alessandro Natoni; Sandra Healy; Michael O'Dwyer; Corrado Santocanale
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

4.  Claspin recruits Cdc7 kinase for initiation of DNA replication in human cells.

Authors:  Chi-Chun Yang; Masahiro Suzuki; Shiori Yamakawa; Syuzi Uno; Ai Ishii; Satoshi Yamazaki; Rino Fukatsu; Ryo Fujisawa; Kenji Sakimura; Toshiki Tsurimoto; Hisao Masai
Journal:  Nat Commun       Date:  2016-07-12       Impact factor: 14.919

5.  Structural Insight into the MCM double hexamer activation by Dbf4-Cdc7 kinase.

Authors:  Jiaxuan Cheng; Ningning Li; Yunjing Huo; Shangyu Dang; Bik-Kwoon Tye; Ning Gao; Yuanliang Zhai
Journal:  Nat Commun       Date:  2022-03-16       Impact factor: 17.694

6.  Biomarkers for Breast Adenocarcinoma Using In Silico Approaches.

Authors:  Jhansi Pandi; Ajucarmelprecilla Arulprakasam; Ranjithkumar Dhandapani; Saikishore Ramanathan; Sathiamoorthi Thangavelu; Jayaprakash Chinnappan; V Vidhya Rajalakshmi; Saad Alghamdi; Nashwa Talaat Shesha; S Prasath
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-03       Impact factor: 2.629

7.  Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth.

Authors:  Suresh Chava; Suresh Bugide; Parmanand Malvi; Romi Gupta
Journal:  iScience       Date:  2022-07-15

8.  Mechanism of cancer cell death induced by depletion of an essential replication regulator.

Authors:  Sayuri Ito; Ai Ishii; Naoko Kakusho; Chika Taniyama; Satoshi Yamazaki; Rino Fukatsu; Asako Sakaue-Sawano; Atsushi Miyawaki; Hisao Masai
Journal:  PLoS One       Date:  2012-05-04       Impact factor: 3.240

9.  ATR-Chk1-APC/CCdh1-dependent stabilization of Cdc7-ASK (Dbf4) kinase is required for DNA lesion bypass under replication stress.

Authors:  Masayuki Yamada; Kenji Watanabe; Martin Mistrik; Eva Vesela; Iva Protivankova; Niels Mailand; MyungHee Lee; Hisao Masai; Jiri Lukas; Jiri Bartek
Journal:  Genes Dev       Date:  2013-11-15       Impact factor: 11.361

10.  Cdc7 activates replication checkpoint by phosphorylating the Chk1-binding domain of Claspin in human cells.

Authors:  Chi-Chun Yang; Hiroyuki Kato; Mayumi Shindo; Hisao Masai
Journal:  Elife       Date:  2019-12-31       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.